Dr. Lauren Skelly is a Staff Scientist II in the Translational Research group at the Gene Editing Institute. Lauren received her PhD in 2022 from the University of Maryland, College Park. During her doctoral research, she studied the evolutionary basis of phenotypic novelties through protein-protein and protein-RNA interactions and explored DNA editing and RNA labeling. Lauren then went to the FDA Center for Biologics Evaluation and Research (CBER) as a contract research scientist to study novel technologies in RNA editing and detection. Lauren’s research interests include development of patient centered Cas9-based therapeutics and understanding of editing outcomes, as well as novel Cas protein-based therapies.
